GSK completes $20bn three-part asset swap deal with Novartis..... Celgene's lung cancer drug Abraxane gets approval in Europe..... Alizé Pharma begins Phase II trial of AZP-531 to treat Prader-Willi syndrome..... Aquinox completes patient enrollment in Phase II LEADERSHIP trial of AQX-1125 to treat BPS/IC..... BioLineRx seeks German approval to begin Phase IIb trial of leukemia drug candidate BL-8040..... Eisai introduces thyroid cancer drug Lenvima in US..... Kite Pharma expands CRADA with NCI for new cancer immunotherapy products..... CEL-SCI gets clearance to conduct Phase III trial of cancer drug Multikine in 21 countries..... GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge..... Post-Novartis deal, GSK's top dog in vaccines, consumer health. Now what?..... Teva deal with G&W saves plant and 280 jobs in Pennsylvania..... AstraZeneca director pushing to tie exec pay to big growth promises..... Medicare urged to crack down on antipsychotic scripts for dementia sufferers..... Was Onyx worth it? Amgen's case is looking up as Kyprolis bests Velcade in head-to-head trial..... EMA committee issues positive opinion for Novartis' lung cancer drug Zykadia..... Roche gets EMA positive recommendation for Avastin plus chemotherapy to treat cervical cancer..... FDA accepts Bristol-Myers' BLA for Opdivo to treat advanced squamous NSCLC..... Actavis and Medicines360 get FDA approval for pregnancy prevention drug Liletta..... Mylan acquires non-US specialty, branded generics assets from Abbott..... Biogen Idec, Sobi report positive top-line results from Phase III Kids B-LONG trial of Alprolix..... Mundipharma introduces Remsima (infliximab) in six European countries..... Gilead looks overseas to guard Sovaldi profits from taxes..... Sanofi's Toujeo gets the love from EU regulators that FDA withheld..... Bayer nabs new Eylea nod to help it toward 2015 sales target..... Pfizer, Novartis: CDC's MenB nod is too narrow..... Bayer's Eylea wins approval in Europe to treat retinal vein occlusion..... EMA accepts MAA for Amgen's myeloma drug Kyprolis..... Portola's factor Xa inhibitor antidote andexanet alfa gets FDA orphan drug status..... EMA grants orphan drug status for Tolero's leukemia drug alvocidib..... ObsEva releases positive results from Phase I trial of OBE001 to treat preterm labour..... Columbia to begin Phase II trial of lidocaine bioadhesive 10% gel..... Triphase, Sunnybrook to advance development new bi-specific antibody for cancer patients..... Sanofi's fight for Toujeo market share won't be easy, analysts say..... SC's top court backs Risperdal verdict against J&J, but cuts penalty to $136M..... Pharma wins another round in fight against dreaded drug reimportation..... Valeant rolls out prelim data on its newly purchased cancer vaccine Provenge..... GlaxoSmithKline's new chairman will climb aboard months earlier than expected..... Bayer counts on consumer health, pharma growth to power 2015..... GSK CEO Witty's pay whacked as U.K.'s largest drugmaker struggles to right itself..... USPTO issues two patents covering Ocata?s immune-modulatory cell technology..... Amgen reports positive results from Phase III study of AMG 416 with cinacalcet..... Lupin enters into clinical research partnership with Acceliant..... AstraZeneca, Orca to develop new drugs for autoimmune diseases..... Sanofi's diabetes drug Toujeo gets FDA approval..... FDA accepts for review Teva's NDA for pain management tablets..... FDA approves Actavis' antibacterial drug Avycaz to treat cIAI and cUTI..... Eisai's Phase III trial of sarcoma drug Halaven meets primary endpoint..... USPTO issues two patents covering Ocata?s immune-modulatory cell technology..... Amgen reports positive results from Phase III study of AMG 416 with cinacalcet..... Lupin enters into clinical research partnership with Acceliant..... Takeda will grow again in the coming year, COO Weber promises..... California lawmaker calling for more pricing transparency for costly meds..... J&J loses first court battle over Risperdal's breast-growth side effects..... As Shire gears up to push Vyvanse for binge eating, critics worry about abuse..... Sidelined after tampering incident, GSK's alli is back on sale..... Dr. Reddy's drug prices in crosshairs of two states..... Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg..... Ireland's Shire buys Meritage Pharma for $70m..... Merck, MPP to expand access to pediatric formulations of HIV drug raltegravir..... Pfizer's Phase II trial of meningococcal group B vaccine meets co-primary immunogenicity objectives..... Ipsen secures option to buy Canbex Therapeutics..... Teva's Phase IIb chronic migraine trial of TEV-48125 meets primary and secondary endpoints..... Actavis seeks FDA approval to market generic ulcerative colitis drug Uceris..... FDA approves Novartis's multiple myeloma drug Farydak..... Researchers review use of aspirin for cardiovascular disease prevention..... India?s Elder Pharma expands its Solo range of OTC products..... Takeda makes an M&A move in Turkey..... Turning to Twitter, MD Anderson doc launches campaign against cancer drug prices..... Baxter picks HQ for biopharma spinoff, and it's just up the road..... Valeant's low Salix price may leave room for other bids..... Actavis' buyout of Allergan could trigger $100M golden parachute for Pyott..... Consumer group petitions FDA to pull generic antifungal med..... Novartis agrees to FTC?s conditions to acquire GSK?s oncology drugs..... Cyclenium and Fundación MEDINA partner to discover anti-infective drug candidates..... Rigel, Bristol-Myers Squibb partner to develop cancer immunotherapies..... NGM, Merck collaborate to develop biologic therapies for various diseases..... Researchers complete Gardasil 9 HPV vaccine?s international phase 2/3 trial..... New Sanofi chief's ?4M signing bonus 'incomprehensible' to French officials..... Bayer reportedly close to diabetes device sale worth up to $2.3B..... FDA hands Lupin plant 6 black marks, along with ANDA approval..... With Salix buy, Valeant bets $10B on GI market growth..... J&J awaits jury verdict over Risperdal patient's breast development..... Canadian paper backpedals from Gardasil side effects story..... Valeant to buy Salix Pharmaceuticals for $14.5bn..... Researchers complete Gardasil 9 HPV vaccine?s international phase 2/3 trial..... Actavis secures final US FDA approval for Buprenorphine sublingual tablets..... Sosei acquires biotechnology company Heptares Therapeutics for $400m..... US FDA accepts Pfizer's sNDA for priority review of Rapamune to treat LAM..... MedImmune, NIST partner to advance drug discovery and manufacturing..... New Sanofi chief's ?4 million signing bonus 'incomprehensible' to French officials..... RSS NEWSFEED....

Welcome to
The Academy of
Pharmaceutical Sciences

The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.

Recent meetings

APS Freeze drying and alternative drying technologies for parenterals

28 January 2015 - Loughborough

Freeze drying - is there an alternative process technology to consider for your biopharmaceuticals?

A very successful one day meeting was held to look at the latest challenges and opportunities in the preservation of biopharmaceuticals. The meeting explored new developments in the established technology of freeze drying and discussed possible alternatives of spray drying, protein crystallisation and supercritical fluid drying of biopharmaceuticals.

Latest News

Chairman's Blog
TUESDAY, 3 MARCH 2015
Your Academy moves on in 2015. . . I am delighted to reflect on the excellent work of the membership of APS in supporting the Focus Groups (FGs) and the new structures of Board and Extended Leadership Team set up at the AGM in 2014 to deliver on a strong programme for 2014-15. This is now available on the website. http://www.apsgb.co.uk/events/default.asp. A report from the first of these events, APS Freeze drying and alternative drying technologies for parenterals, can be viewed on the APS website. http://www.apsgb.co.uk/. The Board and the Extended Leadership Team which includes all the Focus Group Chairs are engaged in a very inclusive process and are working well. The first joint meeting of both in October looked at the programmes and the next in April will look at APS strategy and embed the needs of the focus groups within it. I can’t express strongly enough my thanks to all of you who make the APS work so well - please keep it up.. Each of the Focus groups is currently writing a one pager to highlight their hot topics and suggesting what can be done to work with the wider APS membership on them. These documents will link the day-to-day interests of the FGs and will be available for discussion at the April meeting. I am really keen to try and ensure that all hot topics of interest to our members are captured in the document that Mark McAllister and the FGs are preparing. If you are not a member of a focus group (? why not?) please send your ideas and suggestions to Carol O’ Connor (carol@apsgb.org) or me and we will make sure they get discussed. APS is an organisation run for the members by the members and you all have a voice.. Much of the science which interests our members has the patient at its heart. We are often asked how does our particular science work for the benefit of the patient and I’m interested to hear your views. This theme was at the heart of our PharmSci conference in 2014 with a thought provoking lecture by the Science Chair, Linda Hakes. We will ask each Focus Group to consider if there is a strand or an aspect of their interest which could reflect this theme and we hope that this material will form the basis of articles we can use to publicise APS.. A really good example of our facilitation role is the current project funded by Innovate UK on paediatric formulation where we worked to engage the participants and will have a strong role to communicate the project results to the wider community.. Of course a lot of our other scientific interests do not link directly to patients but we do have communities which serve the food, cosmetics and materials sectors and it would be good to be able to make statements on their behalf too.. You will see from this blog I am trying to gain material to show the leading sectoral interest groups the added value which the Academy provides. It is important in these days of effective cost control that our value is clear and helpful and I will continue to work with you to ensure that our message is strong.. The programme for PharmSci has just gone up on the website http://www.ukpharmsci.org/ and is a strong one focussed on innovation and led by this year’s Science Chair, David Jones from Queens University, Belfast. Last year we had a good range of exciting science in the poster session and I would encourage our young scientists and their supervisors to submit their abstracts http://www.ukpharmsci.org/Abstracts in good time. There has been a real buzz about our conference each year and this year, in East Midlands Conference Centre, I’m sure it will be the same. I look forward to meeting you there.. Bill Dawson, Chair, APS.

DMU 3rd Quality by Design Symposium
MONDAY, 16 FEBRUARY 2015
24th & 25th March 2015 Leicester Tigers, Leicester After two successful symposia in 2013/2014 we are delighted to be hosting the Third Quality by Design Symposium on March 24-25th 2015. We planned this event to bring together academics, regulators and industrial experts to share academic research aligned to the QbD agenda as well as progress in ‘real life’ QbD implementation. The meeting will focus on Continuous Process and Biopharmaceuticals. Attendees’ remarks from the 2nd symposium in April 2014: •“I thoroughly enjoyed the day and I learnt a lot. I will be there for sure next year” •“It was perfectly organised and attracted a lot of interesting people” •“Engaging senior leaders from the big Pharma is really important. The Symposium was very enjoyable, great speakers and a great opportunity to catch up with people” Why Attend? •Last year 120 delegates attended the symposium (70% from industry) •Learn from senior leaders from industry about the latest development in Biopharmaceuticals and Continuous Manufacturing •Network, build relationships and collaborative opportunities Contacts Walkiria Schlindwein – Chair E: wss@dmu.ac.uk Jude Lewis – Administrator E: jlewis@dmu.ac.uk General Enquiries E: qbd@dmu.ac.uk http://www.qbd-dmu.co.uk/symposium-2015/enrol-now/.

APS Industrial Insights 2015
FRIDAY, 6 FEBRUARY 2015
16-17th April. PFIZER AT DISCOVERY PARK, SANDWICH. Two day event for undergraduate and postgraduate students exploring opportunities in the pharmaceutical industry. As a student attending you are able to get a first-hand insight into the Pharmaceutical Industry by a series of talks by key people within the Pharmaceutical Industry and a tour of the pharmaceutical research and manufacturing facilities at Discovery Park.. Choosing the right career path...A done deal or still deciding?. Industrial Insights 2015 offers opportunities to present a poster of your work, network with experienced pharmaceutical scientists including members of the NSFG committee, and have your CV reviewed by an industry professional.. Industrial Insights is organised by The Academy of Pharmaceutical Sciences New Scientist Focus Group (NSFG).. Feedback from Industrial Insights 2014 “A mind-blowing experience which gave me the unique opportunity to explore a wide range of career options available within the pharmaceutical industry and most importantly, network with pharmaceutical scientists from various fields.”. “A must go to event for those passionate about pursuing a career in the pharmaceutical industry: insightful, informative and enjoyable!”. For further information, to see the programme and to register, please visit us online here:. http://www.apsgb.co.uk/EVENTS/20150416/. .

APS Particle Engineering - Joint Meeting with SSPC
MONDAY, 2 FEBRUARY 2015
Venue: Trinity College, Dublin Monday 13th and Tuesday 14th April 2015. Particle engineering: the first stage for successful pharmaceutical formulation The delivery of a robust formulation process which successfully delivers the active ingredient reproducibly throughout the shelf life of a product is a challenge that formulation scientists face every day. Quite frequently variable input materials need to be “accommodated” by adjusting the formulation process or, even worse failure in performance testing can result in failed batches and potentially delays in supplying the market. By controlling, or even designing the input material a number of opportunities where simpler and cheaper formulations/processes, more rapid development and more robust processes can begin to emerge. Engineering of formulations that have reproducible or even predictable performance should start during the particle formation stage. Historically drug substance and drug product groups have worked very separately but more recently a firm collaboration can help identify the “right particles” and methods to produce them on scale. This symposium will provide world leading knowledge and case studies from both academia and industry in all the key aspects around particle engineering: Particle formation, isolation/drying, particle processing, particle assessment and particle performance. It is a must attend for both scientists and managers in pharmaceutical development and manufacture and will also appeal to scientific community in related industries such as food, FMCG and agrochemicals. This meeting is a partnership event bringing together the Materials Science Focus Group of the APS with the Solid State Pharmaceutical Cluster of Ireland. Opportunities will be available for displaying posters and also for exhibitors of scientific equipment/services. Please contact APS secretariat for more details. The event is to be held at Trinity College Dublin and as this is a partnership event demand is likely to be high for the limited places hence please be sure to reserve your place early to avoid disappointment.. For full details, please visit us on line here: http://www.apsgb.co.uk/EVENTS/20150413/Default.asp.

Upcoming Events

APS Bioequivalence of Orally Inhaled Drug Products: Joint Meeting with The Aerosol Society
30 March 2015

APS Particle Engineering - Joint Meeting with SSPC
13 - 14 April 2015

APS Industrial Insights 2015
16 - 17 April 2015

APS Board Meeting
28 - 29 April 2015

APS Parkinson's Disease: From Patient to Product
19 May 2015

Vacancies

View all Vacancies
Advertise your job vacancies